Roche Recalls Viracept - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Roche Recalls Viracept


ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Basel, Switzerland (June 6)—Roche, in an agreement with the European Medicines Agency (EMEA, London) and the Swiss Agency for Therapeutic Products (Swissmedic, Bern, Switzerland), recalled all batches of “Viracept” (nelfinavir) powder and tablets in Europe and some other regions of the world.

Viracept is a protease inhibitor supplied by Roche outside the United States and Canada. The United States, Canada, and Japan are not affected by the recall.

Roche received several reports that some batches of Viracept 250-mg tablets had a strange odor. A chemical analysis of the affected tablets showed they contained higher than normal levels of methane sulfonic acid ethylester.

Ethyl mesylate is a genotoxic substance, according to EMEA. “The level of risk to patients resulting from this contamination is difficult to measure, and is currently under further evaluation,” said EMEA in a press release.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here